ClearPoint Neuro, Inc. (CLPT) Tops Q3 EPS by 4c; Offers FY22 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ClearPoint Neuro Reports Third Quarter 2022 Results
November 8, 2022 4:05 PM ESTSOLANA BEACH, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the Company), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2022.
Third Quarter Highlights
Reported quarterly revenue of $5.1 million, a 13% year-over-year increase;Partner PTC Therapeutics gene therapy treatment Upstaza was granted full marketing authorization by the European Commission. Upstaza will be administered with the Companys SmartFlow® Neuro... More